SG11201704597WA - Agonistic tnf receptor binding agents - Google Patents
Agonistic tnf receptor binding agentsInfo
- Publication number
- SG11201704597WA SG11201704597WA SG11201704597WA SG11201704597WA SG11201704597WA SG 11201704597W A SG11201704597W A SG 11201704597WA SG 11201704597W A SG11201704597W A SG 11201704597WA SG 11201704597W A SG11201704597W A SG 11201704597WA SG 11201704597W A SG11201704597W A SG 11201704597WA
- Authority
- SG
- Singapore
- Prior art keywords
- receptor binding
- binding agents
- tnf receptor
- agonistic
- agonistic tnf
- Prior art date
Links
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 title 1
- 230000001270 agonistic effect Effects 0.000 title 1
- 239000011230 binding agent Substances 0.000 title 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Wood Science & Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2015050255 | 2015-01-08 | ||
| PCT/EP2016/050308 WO2016110584A1 (en) | 2015-01-08 | 2016-01-08 | Agonistic tnf receptor binding agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201704597WA true SG11201704597WA (en) | 2017-07-28 |
Family
ID=55072677
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201704597WA SG11201704597WA (en) | 2015-01-08 | 2016-01-08 | Agonistic tnf receptor binding agents |
| SG10202003171TA SG10202003171TA (en) | 2015-01-08 | 2016-01-08 | Agonistic tnf receptor binding agents |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202003171TA SG10202003171TA (en) | 2015-01-08 | 2016-01-08 | Agonistic tnf receptor binding agents |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10457735B2 (en) |
| EP (3) | EP3242890B1 (en) |
| JP (4) | JP6744326B2 (en) |
| KR (3) | KR20240028548A (en) |
| CN (3) | CN109476761B (en) |
| AU (2) | AU2016205974B2 (en) |
| BR (1) | BR112017013189B1 (en) |
| CA (2) | CA3224830A1 (en) |
| CY (1) | CY1122399T1 (en) |
| DK (2) | DK3242890T3 (en) |
| ES (2) | ES2755527T3 (en) |
| HR (2) | HRP20220811T1 (en) |
| HU (2) | HUE059219T2 (en) |
| LT (1) | LT3623386T (en) |
| ME (1) | ME03576B (en) |
| MX (2) | MX2017008917A (en) |
| PL (2) | PL3623386T3 (en) |
| PT (2) | PT3242890T (en) |
| RS (2) | RS59693B1 (en) |
| RU (2) | RU2020115901A (en) |
| SG (2) | SG11201704597WA (en) |
| SI (2) | SI3242890T1 (en) |
| WO (1) | WO2016110584A1 (en) |
| ZA (1) | ZA201704797B (en) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| AU2014205086B2 (en) | 2013-01-14 | 2019-04-18 | Xencor, Inc. | Novel heterodimeric proteins |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| EP3954713A3 (en) | 2014-03-28 | 2022-03-30 | Xencor, Inc. | Bispecific antibodies that bind to cd38 and cd3 |
| CA2967426A1 (en) | 2014-11-26 | 2016-06-02 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and tumor antigens |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| BR112017011166A2 (en) | 2014-11-26 | 2018-02-27 | Xencor, Inc. | heterodimeric antibodies that bind to cd3 and cd38 |
| SG11201708804WA (en) | 2015-05-07 | 2017-11-29 | Agenus Inc | Anti-ox40 antibodies and methods of use thereof |
| CN108883173B (en) | 2015-12-02 | 2022-09-06 | 阿吉纳斯公司 | Antibodies and methods of use thereof |
| EP3387013B1 (en) | 2015-12-07 | 2022-06-08 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and psma |
| CN108601731A (en) | 2015-12-16 | 2018-09-28 | 磨石肿瘤生物技术公司 | Discriminating, manufacture and the use of neoantigen |
| MX2018012897A (en) * | 2016-04-22 | 2019-01-17 | Alligator Bioscience Ab | Novel bispecific polypeptides against cd137. |
| MX2018015592A (en) | 2016-06-14 | 2019-04-24 | Xencor Inc | Bispecific checkpoint inhibitor antibodies. |
| CA3029328A1 (en) | 2016-06-28 | 2018-01-04 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
| CN109641959B (en) | 2016-07-14 | 2023-08-22 | 健玛保 | Multispecific antibodies to CD40 and CD137 |
| WO2018045110A1 (en) * | 2016-08-30 | 2018-03-08 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| CN110267990B (en) * | 2016-08-30 | 2023-11-07 | Xencor股份有限公司 | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| BR112019005895A2 (en) * | 2016-09-23 | 2019-06-11 | Merus N.V. | binding molecules that modulate a biological activity expressed by a cell |
| CA3041340A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
| US10576161B2 (en) | 2017-01-20 | 2020-03-03 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD137+ cells |
| CN110382541A (en) * | 2017-03-29 | 2019-10-25 | 葛莱高托普有限公司 | Humanization anti-CD 40 antibodies |
| CN111148763B (en) | 2017-07-20 | 2023-11-03 | Aptevo研究与开发公司 | Antigen binding proteins that bind to 5T4 and 4-1BB and related compositions and methods |
| MX2020001198A (en) | 2017-08-04 | 2020-09-07 | Genmab As | Binding agents binding to pd-l1 and cd137 and use thereof. |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to bcma and uses thereof |
| EP3676294A4 (en) * | 2017-08-28 | 2021-12-22 | Systimmune, Inc. | Anti-cd3 antibodies and methods of making and using thereof |
| KR20200087143A (en) | 2017-10-10 | 2020-07-20 | 그릿스톤 온콜로지, 인코포레이티드 | Identification of new antigens using hot spots |
| EP3706793A1 (en) | 2017-11-08 | 2020-09-16 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-pd-1 sequences |
| US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| CA3083097A1 (en) | 2017-11-22 | 2019-05-31 | Gritstone Oncology, Inc. | Reducing junction epitope presentation for neoantigens |
| WO2019125732A1 (en) | 2017-12-19 | 2019-06-27 | Xencor, Inc. | Engineered il-2 fc fusion proteins |
| AU2019247415A1 (en) | 2018-04-04 | 2020-10-22 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| AU2019256529A1 (en) | 2018-04-18 | 2020-11-26 | Xencor, Inc. | TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains |
| CA3097593A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| AU2019297451A1 (en) | 2018-07-03 | 2021-01-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| JP2022503959A (en) | 2018-10-03 | 2022-01-12 | ゼンコア インコーポレイテッド | IL-12 heterodimer FC-fusion protein |
| CN113454111A (en) | 2018-11-06 | 2021-09-28 | 健玛保 | Antibody formulations |
| WO2020106358A1 (en) | 2018-11-20 | 2020-05-28 | Takeda Vaccines, Inc. | Novel anti-zika virus antibodies and uses thereof |
| WO2020180726A1 (en) | 2019-03-01 | 2020-09-10 | Xencor, Inc. | Heterodimeric antibodies that bind enpp3 and cd3 |
| MX2021012961A (en) | 2019-04-24 | 2021-11-25 | Heidelberg Pharma Res Gmbh | Amatoxin antibody-drug conjugates and uses thereof. |
| US20230087164A1 (en) | 2020-02-04 | 2023-03-23 | Genmab A/S | Antibodies for use in therapy |
| EP4126966A1 (en) * | 2020-03-31 | 2023-02-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Proteomic screening for lysosomal storage diseases |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
| AU2021329378A1 (en) | 2020-08-19 | 2023-03-23 | Xencor, Inc. | Anti-CD28 compositions |
| CN112175080B (en) * | 2020-10-22 | 2021-05-25 | 优睿赛思(武汉)生物科技有限公司 | Human interleukin-6 resistant high affinity rabbit monoclonal antibody and application |
| JP2023551980A (en) | 2020-12-07 | 2023-12-13 | ジェンマブ エー／エス | Antibody and taxon combination therapy |
| EP4305067A1 (en) | 2021-03-09 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
| AU2022233547A1 (en) * | 2021-03-09 | 2023-09-28 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in therapy |
| WO2022192586A1 (en) | 2021-03-10 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
| BR112023020832A2 (en) | 2021-04-08 | 2023-12-19 | Marengo Therapeutics Inc | TCR-BINDED MULTIFUNCTIONAL MOLECULES AND THEIR USES |
| BR112023027006A2 (en) | 2021-06-21 | 2024-03-12 | BioNTech SE | METHOD FOR REDUCE OR PREVENT THE PROGRESSION OF A TUMOR OR TREAT A CANCER IN A SUBJECT, AND, LINKING AGENT |
| WO2024050318A1 (en) * | 2022-08-27 | 2024-03-07 | H. Lee Moffitt Cancer Center And Research Institute | Cd40l 41bbl bispecific proteins |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| WO2003043583A2 (en) * | 2001-11-20 | 2003-05-30 | Seattle Genetics, Inc. | Treatment of immunological disorders using anti-cd30 antibodies |
| CN101023102B (en) * | 2004-09-17 | 2013-05-29 | 霍夫曼-拉罗奇有限公司 | Anti-OX40L antibodies |
| CA2646508A1 (en) * | 2006-03-17 | 2007-09-27 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
| GB0620894D0 (en) * | 2006-10-20 | 2006-11-29 | Univ Southampton | Human immune therapies using a CD27 agonist alone or in combination with other immune modulators |
| EP2626372B1 (en) | 2007-03-29 | 2018-03-21 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| PT2201100E (en) * | 2007-09-14 | 2016-06-03 | Univ Brussel Vrije | Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination |
| CN101918447B (en) * | 2007-12-14 | 2014-06-11 | 布里斯托尔-米尔斯·斯奎布公司 | Binding molecules to the human OX40 receptor |
| US9931386B2 (en) * | 2008-06-16 | 2018-04-03 | Atsuo Ochi | Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity |
| AU2011275749C1 (en) | 2010-07-09 | 2015-09-17 | Aduro Biotech Holdings, Europe B.V. | Agonistic antibody to CD27 |
| CN103347898B (en) * | 2011-01-10 | 2017-12-05 | Ct大西洋有限公司 | Including the therapeutic alliance with tumor associated antigen binding antibody |
| RU2562874C1 (en) * | 2011-08-23 | 2015-09-10 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Antibodies against ox40 and methods of their application |
| GB201116092D0 (en) * | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| RS57840B1 (en) * | 2013-03-18 | 2018-12-31 | Biocerox Prod Bv | Humanized anti-cd134 (ox40) antibodies and uses thereof |
| CN109641959B (en) * | 2016-07-14 | 2023-08-22 | 健玛保 | Multispecific antibodies to CD40 and CD137 |
-
2016
- 2016-01-08 CA CA3224830A patent/CA3224830A1/en active Pending
- 2016-01-08 EP EP16700136.1A patent/EP3242890B1/en active Active
- 2016-01-08 MX MX2017008917A patent/MX2017008917A/en active IP Right Grant
- 2016-01-08 DK DK16700136.1T patent/DK3242890T3/en active
- 2016-01-08 SG SG11201704597WA patent/SG11201704597WA/en unknown
- 2016-01-08 KR KR1020247005611A patent/KR20240028548A/en active Search and Examination
- 2016-01-08 SI SI201630421T patent/SI3242890T1/en unknown
- 2016-01-08 CN CN201680005119.5A patent/CN109476761B/en active Active
- 2016-01-08 ME MEP-2019-278A patent/ME03576B/en unknown
- 2016-01-08 EP EP19194817.3A patent/EP3623386B1/en active Active
- 2016-01-08 KR KR1020217009922A patent/KR102640769B1/en active IP Right Grant
- 2016-01-08 PT PT167001361T patent/PT3242890T/en unknown
- 2016-01-08 PT PT191948173T patent/PT3623386T/en unknown
- 2016-01-08 PL PL19194817.3T patent/PL3623386T3/en unknown
- 2016-01-08 WO PCT/EP2016/050308 patent/WO2016110584A1/en active Application Filing
- 2016-01-08 US US15/538,419 patent/US10457735B2/en active Active
- 2016-01-08 SI SI201631557T patent/SI3623386T1/en unknown
- 2016-01-08 PL PL16700136T patent/PL3242890T3/en unknown
- 2016-01-08 RU RU2020115901A patent/RU2020115901A/en unknown
- 2016-01-08 ES ES16700136T patent/ES2755527T3/en active Active
- 2016-01-08 AU AU2016205974A patent/AU2016205974B2/en active Active
- 2016-01-08 CN CN202311416068.3A patent/CN117843799A/en active Pending
- 2016-01-08 LT LTEP19194817.3T patent/LT3623386T/en unknown
- 2016-01-08 JP JP2017554647A patent/JP6744326B2/en active Active
- 2016-01-08 BR BR112017013189-7A patent/BR112017013189B1/en active IP Right Grant
- 2016-01-08 CN CN201911288299.4A patent/CN111499752A/en active Pending
- 2016-01-08 SG SG10202003171TA patent/SG10202003171TA/en unknown
- 2016-01-08 HU HUE19194817A patent/HUE059219T2/en unknown
- 2016-01-08 RS RS20191503A patent/RS59693B1/en unknown
- 2016-01-08 RU RU2017127792A patent/RU2723131C2/en active
- 2016-01-08 EP EP22167212.4A patent/EP4071176A3/en active Pending
- 2016-01-08 CA CA2969888A patent/CA2969888A1/en active Pending
- 2016-01-08 HU HUE16700136A patent/HUE048532T2/en unknown
- 2016-01-08 RS RS20220653A patent/RS63384B1/en unknown
- 2016-01-08 KR KR1020177021592A patent/KR102238326B1/en active IP Right Grant
- 2016-01-08 ES ES19194817T patent/ES2922398T3/en active Active
- 2016-01-08 DK DK19194817.3T patent/DK3623386T3/en active
- 2016-01-08 HR HRP20220811TT patent/HRP20220811T1/en unknown
-
2017
- 2017-07-05 MX MX2020012240A patent/MX2020012240A/en unknown
- 2017-07-14 ZA ZA2017/04797A patent/ZA201704797B/en unknown
-
2019
- 2019-09-25 US US16/582,534 patent/US10927181B2/en active Active
- 2019-10-09 HR HRP20191824TT patent/HRP20191824T1/en unknown
- 2019-11-13 CY CY20191101191T patent/CY1122399T1/en unknown
-
2020
- 2020-07-30 JP JP2020129222A patent/JP6950056B2/en active Active
-
2021
- 2021-01-08 US US17/144,591 patent/US11814411B2/en active Active
- 2021-09-22 JP JP2021153986A patent/JP7390345B2/en active Active
-
2022
- 2022-01-28 AU AU2022200571A patent/AU2022200571A1/en active Pending
-
2023
- 2023-04-04 JP JP2023060755A patent/JP2023085435A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201704797B (en) | Agonistic tnf receptor binding agents | |
| HK1252161A1 (en) | Chimeric cytokine receptor | |
| ZA201802371B (en) | Glucagon receptor agonists | |
| IL253508B (en) | Agonistic icos binding proteins | |
| HK1252163A1 (en) | Receptor | |
| IL259269A (en) | Improved tnf binders | |
| GB201702617D0 (en) | Receptor | |
| IL272798A (en) | Agonistic tnf receptor binding agents | |
| GB201701887D0 (en) | Receptor | |
| GB201700926D0 (en) | Receptor |